NCOG-03. DESCRIPTIVE ANALYSIS AND OUTCOME COMPARISON BETWEEN PATIENTS WITH GLIOBLASTOMA MULTIFORME WHO RECEIVE 15 VERSUS 30 FRACTIONS OF RADIOTHERAPY: A RETROSPECTIVE CHART REVIEW

NCOG-03. DESCRIPTIVE ANALYSIS AND OUTCOME COMPARISON BETWEEN PATIENTS WITH GLIOBLASTOMA MULTIFORME WHO RECEIVE 15 VERSUS 30 FRACTIONS OF RADIOTHERAPY: A RETROSPECTIVE CHART REVIEW

Abstract The morbidity and efficacy of abbreviated radiotherapy (RT) courses for Glioblastoma (GB) in patients over 60 years have been studied, however, outcomes in younger patients are not yet well-described. This study aims to characterize the outcomes of patients receiving either a standard versu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2024-11, Vol.26 (Supplement_8), p.viii224-viii224
Hauptverfasser: Gnanasegaram, Joshua, Paulin, Gregory, Kutanzi, Ethan, Kalyvas, Maria, Mushonga, Melinda, Genta, Sofia, Purzner, Teresa, Purzner, James, Goldie, Katie, Olding, Timothy, de Moraes, Fabio Ynoe
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page viii224
container_issue Supplement_8
container_start_page viii224
container_title Neuro-oncology (Charlottesville, Va.)
container_volume 26
creator Gnanasegaram, Joshua
Paulin, Gregory
Kutanzi, Ethan
Kalyvas, Maria
Mushonga, Melinda
Genta, Sofia
Purzner, Teresa
Purzner, James
Goldie, Katie
Olding, Timothy
de Moraes, Fabio Ynoe
description Abstract The morbidity and efficacy of abbreviated radiotherapy (RT) courses for Glioblastoma (GB) in patients over 60 years have been studied, however, outcomes in younger patients are not yet well-described. This study aims to characterize the outcomes of patients receiving either a standard versus abbreviated RT course. A retrospective chart review at Kingston Health Sciences Centre from June 2014 to March 2021 included patients with GB receiving either 40Gy in 15 fractions (Fr) or 60Gy in 30Fr. Data on age, ECOG score, and concurrent chemotherapy (Temozolomide, TMZ) were collected. Outcomes compared were treatment completion, hospital admission during treatment, progression-free survival (PFS), and overall survival (OS). Records of 156 patients (median age 61 years, range 25-87 years) were reviewed. Of these, 89 received 30Fr and 67 received 15Fr (p=0.51). MGMT methylation was recorded in 54 (35%) patients; of these, 27 received 15Fr and 27 received 30Fr. Median follow-up was 12 months. While PFS did not significantly differ between 15Fr vs. 30Fr (6 vs. 11 months, respectively; p=0.08), OS was significantly different (8 vs. 16 months, respectively; p
doi_str_mv 10.1093/neuonc/noae165.0885
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_neuonc_noae165_0885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/neuonc/noae165.0885</oup_id><sourcerecordid>10.1093/neuonc/noae165.0885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c835-3399d30c7965064c501c5c30725d859443d0a90ff9ce4be29b991594dbe5eb683</originalsourceid><addsrcrecordid>eNqNkE1uwjAQRq2qlUppT9CNLxBqxzjE3RljiKUQR7YBsYoSE6RWLUGJWPRcvWDDzwG6mRl90vs0egC8YjTCiJG3Q31qDv7t0JQ1jugIxTG9AwNMQxLQOIruL3cYxBRPHsFT130iFGIa4QH4zYReBIiM4ExaYVTu1FpCnvF0a5XtjxnUKyf0UsJ-5NwoqzM4lW4jZQZz7pTMnIUb5RK4SJWeptw6veRwuUqdmmvTg5tEQyOFPDdjCtfS2JWFBMG54cIpnVmo59DwmdIukYbn23fIe8IZbXMpLh-JhBvXZ2slN8_gYV9-dfXLbQ-Bm0snkiDVCyV4GviY0IAQxnYE-QmLKIrGniLsqSdoEtJdTNl4THaoZGi_Z74eV3XIKsZwn--qmtZVFJMhINda3zZd19b74th-fJftT4FRcdZeXLUXN-3FWXtPja5Uczr-C_gDFG16vw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>NCOG-03. DESCRIPTIVE ANALYSIS AND OUTCOME COMPARISON BETWEEN PATIENTS WITH GLIOBLASTOMA MULTIFORME WHO RECEIVE 15 VERSUS 30 FRACTIONS OF RADIOTHERAPY: A RETROSPECTIVE CHART REVIEW</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Gnanasegaram, Joshua ; Paulin, Gregory ; Kutanzi, Ethan ; Kalyvas, Maria ; Mushonga, Melinda ; Genta, Sofia ; Purzner, Teresa ; Purzner, James ; Goldie, Katie ; Olding, Timothy ; de Moraes, Fabio Ynoe</creator><creatorcontrib>Gnanasegaram, Joshua ; Paulin, Gregory ; Kutanzi, Ethan ; Kalyvas, Maria ; Mushonga, Melinda ; Genta, Sofia ; Purzner, Teresa ; Purzner, James ; Goldie, Katie ; Olding, Timothy ; de Moraes, Fabio Ynoe</creatorcontrib><description>Abstract The morbidity and efficacy of abbreviated radiotherapy (RT) courses for Glioblastoma (GB) in patients over 60 years have been studied, however, outcomes in younger patients are not yet well-described. This study aims to characterize the outcomes of patients receiving either a standard versus abbreviated RT course. A retrospective chart review at Kingston Health Sciences Centre from June 2014 to March 2021 included patients with GB receiving either 40Gy in 15 fractions (Fr) or 60Gy in 30Fr. Data on age, ECOG score, and concurrent chemotherapy (Temozolomide, TMZ) were collected. Outcomes compared were treatment completion, hospital admission during treatment, progression-free survival (PFS), and overall survival (OS). Records of 156 patients (median age 61 years, range 25-87 years) were reviewed. Of these, 89 received 30Fr and 67 received 15Fr (p=0.51). MGMT methylation was recorded in 54 (35%) patients; of these, 27 received 15Fr and 27 received 30Fr. Median follow-up was 12 months. While PFS did not significantly differ between 15Fr vs. 30Fr (6 vs. 11 months, respectively; p=0.08), OS was significantly different (8 vs. 16 months, respectively; p&lt;0.001). Patients receiving 15Fr vs 30F tended to have higher ECOG scores (p&lt;0.001) and were older (median: 71 [range 45-87] vs. 57 [range 25-69] years; p&lt;0.001). Individuals receiving TMZ were more likely to receive 30Fr (67.5% vs. 32.5% for 15Fr; p&lt;0.001). Completion rates were higher for 30Fr (94.3%) than 15Fr (83.6%; p=0.03). Hospital admission rates did not differ (p=0.51). In summary, patients receiving 15Fr (40Gy) typically have poorer functional status, are less likely to receive chemotherapy, and less likely to complete treatment compared to those receiving 30Fr. Hospital admission rates during treatment are low (13%) and similar for both groups. OS, but not PFS, is better for patients receiving 30Fr compared to 15Fr.</description><identifier>ISSN: 1522-8517</identifier><identifier>EISSN: 1523-5866</identifier><identifier>DOI: 10.1093/neuonc/noae165.0885</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii224-viii224</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Gnanasegaram, Joshua</creatorcontrib><creatorcontrib>Paulin, Gregory</creatorcontrib><creatorcontrib>Kutanzi, Ethan</creatorcontrib><creatorcontrib>Kalyvas, Maria</creatorcontrib><creatorcontrib>Mushonga, Melinda</creatorcontrib><creatorcontrib>Genta, Sofia</creatorcontrib><creatorcontrib>Purzner, Teresa</creatorcontrib><creatorcontrib>Purzner, James</creatorcontrib><creatorcontrib>Goldie, Katie</creatorcontrib><creatorcontrib>Olding, Timothy</creatorcontrib><creatorcontrib>de Moraes, Fabio Ynoe</creatorcontrib><title>NCOG-03. DESCRIPTIVE ANALYSIS AND OUTCOME COMPARISON BETWEEN PATIENTS WITH GLIOBLASTOMA MULTIFORME WHO RECEIVE 15 VERSUS 30 FRACTIONS OF RADIOTHERAPY: A RETROSPECTIVE CHART REVIEW</title><title>Neuro-oncology (Charlottesville, Va.)</title><description>Abstract The morbidity and efficacy of abbreviated radiotherapy (RT) courses for Glioblastoma (GB) in patients over 60 years have been studied, however, outcomes in younger patients are not yet well-described. This study aims to characterize the outcomes of patients receiving either a standard versus abbreviated RT course. A retrospective chart review at Kingston Health Sciences Centre from June 2014 to March 2021 included patients with GB receiving either 40Gy in 15 fractions (Fr) or 60Gy in 30Fr. Data on age, ECOG score, and concurrent chemotherapy (Temozolomide, TMZ) were collected. Outcomes compared were treatment completion, hospital admission during treatment, progression-free survival (PFS), and overall survival (OS). Records of 156 patients (median age 61 years, range 25-87 years) were reviewed. Of these, 89 received 30Fr and 67 received 15Fr (p=0.51). MGMT methylation was recorded in 54 (35%) patients; of these, 27 received 15Fr and 27 received 30Fr. Median follow-up was 12 months. While PFS did not significantly differ between 15Fr vs. 30Fr (6 vs. 11 months, respectively; p=0.08), OS was significantly different (8 vs. 16 months, respectively; p&lt;0.001). Patients receiving 15Fr vs 30F tended to have higher ECOG scores (p&lt;0.001) and were older (median: 71 [range 45-87] vs. 57 [range 25-69] years; p&lt;0.001). Individuals receiving TMZ were more likely to receive 30Fr (67.5% vs. 32.5% for 15Fr; p&lt;0.001). Completion rates were higher for 30Fr (94.3%) than 15Fr (83.6%; p=0.03). Hospital admission rates did not differ (p=0.51). In summary, patients receiving 15Fr (40Gy) typically have poorer functional status, are less likely to receive chemotherapy, and less likely to complete treatment compared to those receiving 30Fr. Hospital admission rates during treatment are low (13%) and similar for both groups. OS, but not PFS, is better for patients receiving 30Fr compared to 15Fr.</description><issn>1522-8517</issn><issn>1523-5866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNkE1uwjAQRq2qlUppT9CNLxBqxzjE3RljiKUQR7YBsYoSE6RWLUGJWPRcvWDDzwG6mRl90vs0egC8YjTCiJG3Q31qDv7t0JQ1jugIxTG9AwNMQxLQOIruL3cYxBRPHsFT130iFGIa4QH4zYReBIiM4ExaYVTu1FpCnvF0a5XtjxnUKyf0UsJ-5NwoqzM4lW4jZQZz7pTMnIUb5RK4SJWeptw6veRwuUqdmmvTg5tEQyOFPDdjCtfS2JWFBMG54cIpnVmo59DwmdIukYbn23fIe8IZbXMpLh-JhBvXZ2slN8_gYV9-dfXLbQ-Bm0snkiDVCyV4GviY0IAQxnYE-QmLKIrGniLsqSdoEtJdTNl4THaoZGi_Z74eV3XIKsZwn--qmtZVFJMhINda3zZd19b74th-fJftT4FRcdZeXLUXN-3FWXtPja5Uczr-C_gDFG16vw</recordid><startdate>20241111</startdate><enddate>20241111</enddate><creator>Gnanasegaram, Joshua</creator><creator>Paulin, Gregory</creator><creator>Kutanzi, Ethan</creator><creator>Kalyvas, Maria</creator><creator>Mushonga, Melinda</creator><creator>Genta, Sofia</creator><creator>Purzner, Teresa</creator><creator>Purzner, James</creator><creator>Goldie, Katie</creator><creator>Olding, Timothy</creator><creator>de Moraes, Fabio Ynoe</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20241111</creationdate><title>NCOG-03. DESCRIPTIVE ANALYSIS AND OUTCOME COMPARISON BETWEEN PATIENTS WITH GLIOBLASTOMA MULTIFORME WHO RECEIVE 15 VERSUS 30 FRACTIONS OF RADIOTHERAPY: A RETROSPECTIVE CHART REVIEW</title><author>Gnanasegaram, Joshua ; Paulin, Gregory ; Kutanzi, Ethan ; Kalyvas, Maria ; Mushonga, Melinda ; Genta, Sofia ; Purzner, Teresa ; Purzner, James ; Goldie, Katie ; Olding, Timothy ; de Moraes, Fabio Ynoe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c835-3399d30c7965064c501c5c30725d859443d0a90ff9ce4be29b991594dbe5eb683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gnanasegaram, Joshua</creatorcontrib><creatorcontrib>Paulin, Gregory</creatorcontrib><creatorcontrib>Kutanzi, Ethan</creatorcontrib><creatorcontrib>Kalyvas, Maria</creatorcontrib><creatorcontrib>Mushonga, Melinda</creatorcontrib><creatorcontrib>Genta, Sofia</creatorcontrib><creatorcontrib>Purzner, Teresa</creatorcontrib><creatorcontrib>Purzner, James</creatorcontrib><creatorcontrib>Goldie, Katie</creatorcontrib><creatorcontrib>Olding, Timothy</creatorcontrib><creatorcontrib>de Moraes, Fabio Ynoe</creatorcontrib><collection>CrossRef</collection><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gnanasegaram, Joshua</au><au>Paulin, Gregory</au><au>Kutanzi, Ethan</au><au>Kalyvas, Maria</au><au>Mushonga, Melinda</au><au>Genta, Sofia</au><au>Purzner, Teresa</au><au>Purzner, James</au><au>Goldie, Katie</au><au>Olding, Timothy</au><au>de Moraes, Fabio Ynoe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NCOG-03. DESCRIPTIVE ANALYSIS AND OUTCOME COMPARISON BETWEEN PATIENTS WITH GLIOBLASTOMA MULTIFORME WHO RECEIVE 15 VERSUS 30 FRACTIONS OF RADIOTHERAPY: A RETROSPECTIVE CHART REVIEW</atitle><jtitle>Neuro-oncology (Charlottesville, Va.)</jtitle><date>2024-11-11</date><risdate>2024</risdate><volume>26</volume><issue>Supplement_8</issue><spage>viii224</spage><epage>viii224</epage><pages>viii224-viii224</pages><issn>1522-8517</issn><eissn>1523-5866</eissn><abstract>Abstract The morbidity and efficacy of abbreviated radiotherapy (RT) courses for Glioblastoma (GB) in patients over 60 years have been studied, however, outcomes in younger patients are not yet well-described. This study aims to characterize the outcomes of patients receiving either a standard versus abbreviated RT course. A retrospective chart review at Kingston Health Sciences Centre from June 2014 to March 2021 included patients with GB receiving either 40Gy in 15 fractions (Fr) or 60Gy in 30Fr. Data on age, ECOG score, and concurrent chemotherapy (Temozolomide, TMZ) were collected. Outcomes compared were treatment completion, hospital admission during treatment, progression-free survival (PFS), and overall survival (OS). Records of 156 patients (median age 61 years, range 25-87 years) were reviewed. Of these, 89 received 30Fr and 67 received 15Fr (p=0.51). MGMT methylation was recorded in 54 (35%) patients; of these, 27 received 15Fr and 27 received 30Fr. Median follow-up was 12 months. While PFS did not significantly differ between 15Fr vs. 30Fr (6 vs. 11 months, respectively; p=0.08), OS was significantly different (8 vs. 16 months, respectively; p&lt;0.001). Patients receiving 15Fr vs 30F tended to have higher ECOG scores (p&lt;0.001) and were older (median: 71 [range 45-87] vs. 57 [range 25-69] years; p&lt;0.001). Individuals receiving TMZ were more likely to receive 30Fr (67.5% vs. 32.5% for 15Fr; p&lt;0.001). Completion rates were higher for 30Fr (94.3%) than 15Fr (83.6%; p=0.03). Hospital admission rates did not differ (p=0.51). In summary, patients receiving 15Fr (40Gy) typically have poorer functional status, are less likely to receive chemotherapy, and less likely to complete treatment compared to those receiving 30Fr. Hospital admission rates during treatment are low (13%) and similar for both groups. OS, but not PFS, is better for patients receiving 30Fr compared to 15Fr.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/neuonc/noae165.0885</doi></addata></record>
fulltext fulltext
identifier ISSN: 1522-8517
ispartof Neuro-oncology (Charlottesville, Va.), 2024-11, Vol.26 (Supplement_8), p.viii224-viii224
issn 1522-8517
1523-5866
language eng
recordid cdi_crossref_primary_10_1093_neuonc_noae165_0885
source Oxford University Press Journals All Titles (1996-Current)
title NCOG-03. DESCRIPTIVE ANALYSIS AND OUTCOME COMPARISON BETWEEN PATIENTS WITH GLIOBLASTOMA MULTIFORME WHO RECEIVE 15 VERSUS 30 FRACTIONS OF RADIOTHERAPY: A RETROSPECTIVE CHART REVIEW
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A08%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NCOG-03.%20DESCRIPTIVE%20ANALYSIS%20AND%20OUTCOME%20COMPARISON%20BETWEEN%20PATIENTS%20WITH%20GLIOBLASTOMA%20MULTIFORME%20WHO%20RECEIVE%2015%20VERSUS%2030%20FRACTIONS%20OF%20RADIOTHERAPY:%20A%20RETROSPECTIVE%20CHART%20REVIEW&rft.jtitle=Neuro-oncology%20(Charlottesville,%20Va.)&rft.au=Gnanasegaram,%20Joshua&rft.date=2024-11-11&rft.volume=26&rft.issue=Supplement_8&rft.spage=viii224&rft.epage=viii224&rft.pages=viii224-viii224&rft.issn=1522-8517&rft.eissn=1523-5866&rft_id=info:doi/10.1093/neuonc/noae165.0885&rft_dat=%3Coup_cross%3E10.1093/neuonc/noae165.0885%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/neuonc/noae165.0885&rfr_iscdi=true